Skip to main content

Beta-cell function in juvenile diabetes and obesity

Objective

The number of individuals with obesity and type 2 diabetes mellitus (T2DM) is increasing. An alarming aspect is decline in age of onset of T2DM, which is coupled to rise in childhood obesity. Accentuated insulin secretion is observed early in young obese individuals. In many subjects insulin hypersecretion is evident when insulin sensitivity is essentially normal. Based on these observations we propose insulin hypersecretion as an etiological factor promoting lipid deposition, insulin resistance, cellular dysfunction and death in insulin-producing beta-cells and insulin-target brown adipocytes. Pharmacology-based treatment strategies are limited for this growing patient group and the aim of the proposal is to identify novel strategies reducing insulin hypersecretion, which has not been considered a target for intervention in young obese individuals. To address the issue, pediatric obesity clinics and academic centres with focus on beta-cell biology, brown adipocyte imaging, transcript and protein profiling, genetics, epidemiology and bioinfomatics have formed a consortium with two SMEs specialized on biomarker discovery and clinical trials and one large drug company. In the project well-characterized European patient cohorts of more than 3000 obese children will be further characterized with regard to insulin secretion and brown adipocyte mass. Currently used drugs and new principles of intervention based on novel genes, idenitifed in the project and linked with insulin hypersecretion, will be examined for effects on insulin hypersecretion in translational work including the young obese subjects and isolated human islets. Following comprehensive analysis candidate compounds/principles attenuating insulin hypersecretion will be selected, from which novel therapeutic strategies are expected to emerge. Such therapeutic strategies will be of importance for afflicted individuals and European health economy and lead to new opportunities for European industry.

Field of science

  • /medical and health sciences/clinical medicine/endocrinology/diabetes

Call for proposal

FP7-HEALTH-2011-two-stage
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

UPPSALA UNIVERSITET
Address
Von Kraemers Alle 4
751 05 Uppsala
Sweden
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 2 511 440,70
Administrative Contact
Anders Alderborn (Dr.)

Participants (11)

UNIVERSITE DU LUXEMBOURG
Luxembourg
EU contribution
€ 380 800
Address
2 Avenue De L'universite
4365 Esch-sur-alzette
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Eric Tschirhart (Prof.)
PARACELSUS MEDIZINISCHE PRIVATUNIVERSITAT SALZBURG - PRIVATSTIFTUNG
Austria
EU contribution
€ 110 400
Address
Strubergasse 21
5020 Salzburg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Vera Coreth (Dr.)
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 350 400
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Renata Schaeffer (Ms.)
UNIVERSITAET LEIPZIG
Germany
EU contribution
€ 740 600
Address
Ritterstrasse 26
04109 Leipzig
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Gerhard Fuchs (Mr.)
UNIVERSITE DE GENEVE
Switzerland
EU contribution
€ 546 266,80
Address
Rue Du General Dufour 24
1211 Geneve
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Jean-Charles Sanchez (Dr.)
PROTEOSYS AG

Participation ended

Germany
EU contribution
€ 160 981,50
Address
Carl Zeissstrasse 51
55129 Mainz
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Bernd Matuschek (Mr.)
ASTRAZENECA UK LIMITED
United Kingdom
Address
1 Francis Crick Avenue Cambridge Biomedical Campus
CB2 0AA Cambridge
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Li Wang (Dr.)
REGION UPPSALA
Sweden
EU contribution
€ 311 799,60
Address
Po Box 602
751 25 Uppsala
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Sven-Arne åsman (Dr.)
SCANDINAVIAN CRO AB
Sweden
EU contribution
€ 244 800
Address
Kungsgatan 41
753 21 Uppsala
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ulrika Hammarström Lüllmaa (Ms.)
PIVOT BIOMEDICAL SCIENCE GMBH
Germany
EU contribution
€ 269 690,40
Address
Max-planck-strasse 17
54296 Trier
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Mike Otto (Dr.)
GEMEINNUTZIGE SALZBURGER LANDESKLINIKEN BETRIEBSGESELLSCHAFT
Austria
EU contribution
€ 372 600
Address
Mullner Hauptstrasse 48
5020 Salzburg
Activity type
Other
Administrative Contact
Christoph Mandlier (Mr.)